Daniel Schultz, the FDA's chief device regulator, says new medical devices don't need the large-scale exhaustive trials of the drug industry because it is easier to predict the behavior of a machine than it is to track the chemical interactions of a new drug in the body.

FORBES: On The Cover/Top Stories